



## Acceleron to Participate in the 38th Annual J.P. Morgan Healthcare Conference

January 6, 2020

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 6, 2020-- Acceleron Pharma Inc. (Nasdaq:XLRN) today announced that senior management will participate at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, California.

- On Monday, January 13, 2020, Habib Dable, Acceleron's President and Chief Executive Officer, will present an overview of the company at 9:30 a.m. PST / 12:30 p.m. EST.
- Immediately following the presentation, the senior management team will participate in a question and answer breakout session at 10:00 a.m. PST / 1:00 p.m. EST.

A live webcast of the presentation and breakout session will be accessible under "Events and Presentations" in the Investors & Media page of the Company's website at [www.acceleronpharma.com](http://www.acceleronpharma.com). A replay of the webcasts will be available approximately two hours after the event on the Acceleron website.

### About Acceleron

Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. The Company's leadership in the understanding of TGF-beta superfamily biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair.

Acceleron focuses its research and development efforts in hematologic, neuromuscular, and pulmonary diseases. In hematology, Acceleron and its global collaboration partner, Bristol-Myers Squibb, are co-promoting newly approved REBLOZYL® (luspatercept-aamt), the first and only approved erythroid maturation agent, in the United States and are developing luspatercept for the treatment of chronic anemia in myelodysplastic syndromes and myelofibrosis. Acceleron is also advancing its neuromuscular program with ACE-083, a locally-acting Myostatin+ agent in Phase 2 development in Charcot-Marie-Tooth disease and is conducting a Phase 2 pulmonary program with sotatercept in pulmonary arterial hypertension.

For more information, please visit [www.acceleronpharma.com](http://www.acceleronpharma.com). Follow Acceleron on Social Media: [@AcceleronPharma](https://twitter.com/AcceleronPharma) and [LinkedIn](https://www.linkedin.com/company/acceleron-pharma).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20200106005182/en/>

Source: Acceleron Pharma

Acceleron Pharma Inc.

Investors:

Todd James, 617-649-9393

Vice President, Investor Relations and Corporate Communications

Ed Joyce, 617-649-9242

Director, Investor Relations

Media:

Matt Fearer, 617-301-9557

Director, Corporate Communications